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Mental capacity to consent to treatment and the
association with outcome: a longitudinal study in
patients with anorexia nervosa
Isis F.F.M. Elzakkers, Unna N. Danner, Lot C. Sternheim, Daniel McNeish, Hans W. Hoek and
Annemarie A. van Elburg
Background
Relevance of diminished mental capacity in anorexia nervosa
(AN) to course of disorder is unknown.
Aims
To examine prognostic relevance of diminished mental
capacity in AN.
Method
A longitudinal study was conducted in 70 adult female patients
with severe AN. At baseline, mental capacity was assessed by
psychiatrists, and clinical and neuropsychological data
(decision-making) were collected. After 1 and 2 years, clinical
and neuropsychological assessments were repeated, and
remission and admission rates were calculated.
Results
People with AN with diminished mental capacity had a less
favourable outcome with regard to remission and were
admitted more frequently. Their appreciation of illness
remained hampered. Decision-making did not improve, in
contrast to people with full mental capacity.
Conclusions
People with AN with diminished mental capacity seem to do
less well in treatment and display decision-making deficiencies
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Anorexia nervosa (AN) is a severe psychiatric illness usually
beginning in adolescence with a lifetime prevalence among 1 to
4% of females in Europe.1,2 Intense fear of weight gain, body image
disturbance and disturbed cognitive and emotional functioning are
central features of the disorder. These features lead to weight loss
behaviours such as dietary restriction, purging or excessive physi‐
cal activity.3 Acute and chronic effects of starvation complicate
treatment of people with AN, and the standardised mortality ratio
is around 5.5.4,5 In older adolescents and adults, AN commonly has
a relapsing or protracted course,6 and only 50% of the adults
recover completely.7 Psychiatric comorbidity is the rule with mood
disorders (nearly 75% of people with AN) and a range of anxiety
disorders (between 25 and 75%) being most common.8,9 Mean
duration of illness is nearly 7 years,6,10 and as this disorder usually
starts in adolescence, transition to adult life is fraught with
difficulties finishing education, starting a job or engaging in
relationships.
Patients are typically reluctant to engage in treatment,
especially when it has a clear focus on weight gain, and this
tendency to avoid treatment is reflected in the finding that only a
minority is treated within the mental healthcare system.11,12
Where onset of the disorder is triggered by genetic, psychosocial
and interpersonal factors, changes in neural networks sustain the
illness. Altered reward processing to modulate emotional dis-
tress,13,14 increased compulsivity because of being severely under-
weight15 and neuropsychological difficulties16–21 might lead to the
typical persistence of people with AN in their self-destructive
behaviour. Final factors of importance are the altered values
towards life and death in people who are currently ill with AN as
opposed to recovered people with AN and the sense that the AN is
part of the personal identity instead of an acquired illness.22,23
These findings together with the obvious severity of the
disorder lead to doubts regarding decision-making abilities or, in
other words, mental capacity to consent to treatment. These are
relevant doubts, as only a person with full mental capacity with
regard to the medical issue at hand can refuse or consent to
necessary treatment according to most international health legisla-
tions. Assessment of mental capacity generally considers four
abilities:24 the ability to understand information provided regard-
ing illness and treatment; the ability to appreciate this information
as relevant to one’s own situation; the ability to reason with this
information, weighing the consequence of decisions; and the ability
to express a choice about treatment. A semi-structured interview
has been developed to aid clinicians in the assessment of mental
capacity to consent to treatment judging these four abilities
(MacCAT-T25). Although in general psychiatry a number of
studies have been done (for a review see Okai et al26), in AN
studies have been scarce. Two small studies have been done in
adolescents, with inconsistent results.27,28 In the study by Tan et al,
mental capacity of people with AN was excellent, whereas in the
study by Turrell et al impairments in reasoning were shown.
It is tempting to assume that the presence of diminished
mental capacity to consent to treatment is relevant to treatment
outcome, but this has not yet been studied. Therefore, a long-
itudinal study was conducted in our treatment centre. Baseline
results from this sample of 70 adult people who are severely ill with
AN were reported on previously.29 One-third of participants had
diminished mental capacity at baseline (as assessed by psychia-
trists). Diminished mental capacity was associated with a lower
body mass index (BMI), more previous treatment for AN and a
lower appreciation of disorder and treatment; duration of illness
did not differ between the groups.
Although BMI was significantly different between the two
mental capacity groups, still 43% of participants with a BMI below
15 kg/m2 was judged to have full mental capacity, highlighting the
importance of looking further than BMI alone in the assessment
of mental capacity to consent to treatment in AN. The picture that
emerged from these baseline data was that a significant group of
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participants had diminished mental capacity and that not only
BMI was of importance (as yet not clear in what way) but also the
ability to use one’s emotions to come to adaptive decision-making.
What also became clear was that almost all participants (92%) did
follow the treatment advice (whether this was in-patient or out-
patient treatment), suggesting that agreement with the treatment
advice does not necessarily mean possessing full mental capacity.
More insight in possible differences between the two mental
capacity groups in the course of the disorder is relevant to clinical
practice as treatment may need to be tailored more to specific
needs of the group with diminished mental capacity. The initial
group of 70 participants was divided into two groups on the basis
of clinical judgment, one with diminished mental capacity and
one with full mental capacity to consent to treatment. In this
longitudinal part of the study, we aim to answer the following
questions:
(1) Is the course of disorder different between the two mental
capacity groups on clinical variables (BMI, percentage of in-
patient treatment, duration of in-patient stay, remission rate
and eating disorder pathology)?
(2) Is the course of disorder different on psychological
variables (symptoms of depression, anxiety and alexithymia)?
(3) Is the course of disorder different on decision-making
(appreciation of illness and treatment and more general
assessment of decision-making ability)?
Method
The study design has been described in detail elsewhere.29 A
longitudinal cohort study was conducted in our national specialist
centre for the treatment of eating disorders and at baseline 70
consecutively referred female adults with AN were included.
Males (5% of referrals) were excluded to increase homogeneity of
the sample. Treatment offered in our centre follows guidelines
for eating disorders and entails a range of individual and group
therapies, psychomotor therapy and attention to rehabilitation on
an out-patient, day patient or in-patient basis. For a description of
baseline characteristics, see Table 1. The study was conducted in
accordance with the ethical standards described by the Medical
Research Involving Human Subjects Act (WMO) and was approved
by the institutional review board. After complete description of the
study to the participants, written informed consent was obtained.
One and 2 years after inclusion, participants were contacted by
phone and asked for their cooperation with the follow-up
measurements. Some of the required data were collected from
patient files (e.g. current BMI, medication, days of in-patient
treatment), other were collected during assessments by psychia-
trists and psychologists (e.g. interviews and the decision-making
task). When patients were no longer in treatment at our centre,
data on current treatment, BMI and medication were asked
from them.
Clinical measures
Severity of eating disorder symptoms was rated with the Eating
Disorder Examination Questionnaire (EDEQ30,31) and the BMI (in
kg/m2) as measured by the Digital Tanita scale (Tanita Coopera-
tion of America, Inc., Arlington Heights, IL). Eating disorder
treatments and admissions were collected from the participants
and from their files (when available), social functioning from the
social history. Remission rates were assessed. Full remission was
defined as having a weight in the normal range (BMI 18.5–25 kg/m2),
having resumed menses (or likely to when contraception was
used and weight was in the normal range) and having no more
disabling anorectic cognitions (assessed in an interview). Partial
remission was defined as having two out of three of these criteria.
The presence of legal measures regarding their AN was asked
for. Depression and anxiety levels were measured with the Beck
Depression Inventory (BDI-II32) and Spielberger Stait Trait
Anxiety Inventory (STAI33), respectively. Furthermore, levels of
alexithymia were assessed with the Toronto Alexithymia Scale
(TAS34,35).
Mental capacity
At baseline, mental capacity to consent to treatment was assessed
by psychiatrists experienced in the treatment of severe eating
disorders. Based on this assessment, two groups were distin-
guished: a group with full mental capacity to consent to treatment
and a group with diminished mental capacity to do so. At
baseline, the MacArthur Competence Assessment Tool-Treatment
(MacCAT-T25) was used. The MacCAT-T is a semi-structured
interview designed to aid clinicians in determining the level of
Table 1 Baseline characteristics of participants
Total group (n=70) Full MC (n=46) Diminished MC (n=24) P
Age, years: mean (s.d.) 27.3 (9.7) 26.2 (9.3) 29.4 (10.3) 0.19
Age at illness onset (years): mean (s.d.) 17.8 (4.9) 17.7 (4.6) 18.1 (5.7) 0.82
Duration of illness (years): mean (s.d.) 8.6 (8.1) 8.5 (8.2) 8.9 (7.9) 0.84
BMI: mean (s.d.) 15.5 (1.9) 16.1 (1.6) 14.2 (1.9) <0.001
EDE: mean (s.d.) 3.6 (1.3) 3.7 (1.4) 3.5 (1.2) 0.59
ANR/ANP, % 49/51 47/53 55/45 0.55
Previous ED treatment, % 74 65 91 0.02
Previous hospitalisation, % 46 36 65 0.02
Medication, % 58 52 68 0.22
Relationship, % 37 43 24 0.13
Welfare, % 25 11 53 0.001
BDI: mean (s.d.) 29.9 (13.8) 28.8 (13.2) 32.1 (14.9) 0.35
STAI trait: mean (s.d.) 59 (10.7) 59.3 (10.7) 58.4 (10.9) 0.73
STAI state: mean (s.d.) 56.7 (12.8) 56.6 (12.7) 56.9 (13.3) 0.94
TAS: mean (s.d.) 61.3 (9.2) 61.4 (9.2) 61.2 (9.4) 0.94
MacCAT-T appreciation: mean (s.d.) 3.71 (0.62) 3.82 (0.44) 3.48 (0.85) 0.03
Depressive disorder, % 48.4 45.6 55.6 0.47
PTSD, % 23.3 23.8 22.2 0.89
MC, mental capacity; BMI, body mass index; EDE, Eating Disorder Examination; ANR, anorexia nervosa restrictive type; ANP, anorexia nervosa purging type; ED, eating disorder; BDI,




mental capacity to consent to treatment. It has good interrater reli‐
ability and construct validity and has been used in mental capacity
studies in several psychiatric populations.26 As previously reported,29
appreciation of disorder and treatment was significantly lower in the
group with diminished mental capacity. Therefore, we repeated this
MacCAT-T measurement at follow-up. This was done in a face-to-
face interview, when this was not feasible it was done by phone.
Decision-making
The Iowa Gambling Task (IGT36) was used to assess decision-
making ability. The task requires participants to choose a card
from four different decks and with each choice they win and
sometimes also lose money. Two decks are more advantageous,
whereas the other two decks are disadvantageous in the long run
and participants have to find this out by relying on their ‘gut
feeling’. Decision-making is determined by calculating the net
score for all 100 trials as the difference in number of choices
between the advantageous and disadvantageous decks.
Statistical analysis
A fully direct Bayes approach (FDB) was used to optimally account
for the sample size and missing data attributable to attrition.37
Each outcome of interest was fitted as a separate univariate model.
There was no a priori hypothesis for the growth trajectory over
time, so latent basis models were fitted, allowing the data to
determine linear or non-linear growth. BMI is included as a control
variable in all models to satisfy the assumption that missing values
are missing at random. Prior distributions were formed using the
method of McNeish38, and models were fit in Mplus 7.1 with a
Bayesian MCMC (Markow chain Monte Carlo) algorithm with a
Gibbs Sampler and two chains with 50 000 MCMC iterations per
chain. Bayesian estimation was utilised, so frequentist P-values
are unavailable. To keep reporting of results succinct and familiar
to readers unfamiliar with Bayesian statistics, we report Bayesian
P-values (PB). These P-values are based on the quantiles of the
posterior distribution rather than area beyond a test statistic under a
null distribution (as with frequentist P-values). Thus, ‘significance’ in
our results refers to a value of 0 being highly unlikely in the posterior
distribution rather than rejecting the null hypothesis in a frequentist
setting, which are conceptually related but not identical.39
Results
Sample characteristics
After 1 year, 56 people (80%) agreed to cooperate again and after 2
years 50 people (71%) of the original 70 participants (see Fig. 1).
After 1 year, 57 of the people (82%) were still in care for their
eating disorder and after 2 years 48 (69%); this was not signifi‐
cantly different between the two groups (P=0.39 and P=0.91, res‐
pectively). Only one participant in our study was held under the
Mental Health Act (MHA) at baseline, not because of his or her
eating disorder, but because of comorbid alcohol dependence.
No one was held under a section of the MHA during follow-up.
In the first year of follow-up, one patient died of AN-related
complications. We know that after the end of the study (after the
second follow-up), another patient died. Both were judged to have
diminished mental capacity to consent to treatment at baseline and
had a BMI below 15 kg/m2.
Is the course of disorder different with respect to
clinical variables?
Body mass index
Figure 2 shows results from an unconditional growth model for
BMI. Both groups show a significant increase in BMI from baseline
to the Year 1 (PB<0.001) but a non-significant change from Year 1
to Year 2 (PB=0.38). The growth over time was not significantly
different between the groups (PB=0.70). The diminished mental
capacity group had a significantly lower BMI at baseline than the
full mental capacity group (14.2 kg/m2, PB<0.001), and this
significant difference persisted over time. In DSM-5 terminology,
this represents on average a change in category from moderate to
mild for the group with full mental capacity and from extreme to
moderate for the group with diminished mental capacity. The fit of
the model was quite good with a posterior predicted P (PPP) value
of 0.542 (PPP ranges from 0 to 1 and 0.50 is ideal).
In-patient treatment
Difficulties with sample size and missing data were too great to
fit a growth model with this outcome, so we fit models separately
at each time point. At both follow-up time points, the group
with diminished mental capacity had a borderline significant
increase in the probability of having received in-patient treatment
after controlling for BMI at baseline (after 1 year 63% v. 47%,
PB=0.053; after 2 years, 37% v. 23% PB=0.057). However, after
controlling for previous admissions, this difference was no longer
significant at 1 year follow-up (PB=0.096), but the difference
became more significant after 2 years follow-up (PB=0.034).
Assessed for eligibility (n=150)
Included (n=70)
Included in follow-up 1 (n=56)
Included in follow-up 2 (n=50)
Excluded  (n=80)
Not meeting inclusion criteria (n = 45)
Declined to participate (n= 34)
Other reasons: terminally ill, died 3 
weeks later (n=1)
Declined to participate (n=8)
Lost to follow-up (n=5)
Died (n=1)
Declined to participate (n=3)
Lost to follow-up (n=3)
























Fig. 2 BMI change (in kg/m2) between baseline, ﬁrst follow-up (after
1 year) and second follow-up (after 2 years) between the group with
full mental capacity (full) and the group with diminished mental
capacity (diminished).
149
Mental capacity in anorexia nervosa
Patients with previous admissions were more likely to have been
admitted in the course of 1 year (PB=0.029) and between the first
and second year of follow-up (PB=0.022), regardless of group. After
1 year follow-up, previous admission is largely responsible for
the differences between the groups. Between the first and second
year follow-up, the difference between the groups was not fully
explained by BMI and previous admissions.
Remission rate
Unlike all other models, the remission outcome includes BMI as
part of the criteria. We considered the conceptual appropriate‐
ness of including BMI as a covariate and whether the partial
redundancy would hinder interpretation or estimation of the
model. We ran the model two different ways, one with BMI as a
covariate and one without. The results were quite similar, and
inferential conclusion did not differ between the models. We
therefore report only the model with BMI as a covariate in Table 2.
Similar to the model for in-patient treatment, estimation difficul-
ties required that we fit a separate model to each time point rather
than a single longitudinal model. Remission rate is also a binary
variable, so we used logistic models to determine predicted
probabilities of remission. As shown in Table 2, after 2 years the
group with diminished mental capacity was more likely to show
no remission (53.9% compared with 26.6% in the full mental
capacity group, PB=0.026). Full remission rates were still low (35.8
and 38.9%, respectively) in both groups at 2 year follow-up.
Eating disorder pathology
At the two follow-up measurements, the EDE-Q was measured. In
the analysis BMI was controlled for. The group with full mental
capacity went from an EDEQ global score of 3.08 at follow-up 1 to
2.76 at follow-up 2, which is a non-significant change (PB=0.15).
The group with diminished mental capacity went from 2.59 to
2.27, which is also non-significant (PB=0.27). Eating disorder
pathology as measured by the EDE-Q did not differ between the
groups after 1 year or after 2 years (PB=0.21).
Is the course of disorder different with respect to
psychological variables?
Separate latent growth models were fit to each outcome all
controlling for BMI. Both the full and the diminished mental
capacity group improved significantly after 2 years in depression
score (BDI improved from both 30 to both 20, PB<0.001) and
anxiety score (STAI state improved from 57–54 to 44–42, res‐
pectively, PB<0.001), there are no significant differences between
groups at any time-point (BDI: PB=0.44, STAI: PB=0.42). As shown
in Fig. 3, the full mental capacity groups showed a significant
improvement in alexithymia score (60.8– 48.8, PB<0.001), which
was below the clinical cut-off of 52 for possible alexithymia.34,35
The diminished mental capacity group did not improve (PB=0.10)
and stayed around the clinical cut-off of 61 for alexithymia. The
difference over time between groups was significant (PB=0.006).
The PPP values of the alexithymia, depression and anxiety score
models were 0.41, 0.48 and 0.59, respectively, all indicating
acceptable fit.
Is the course of disorder different with respect to
decision-making?
Decision-making task
Changes in decision-making were modelled with a latent growth
model. Because symptoms of depression and alexithymia may
theoretically have an influence on decision-making ability,40,41 a
model was tested including BDI and TAS next to BMI as control
variables. The group difference at baseline was not significant in
this model (19.0 v. 5.9; PB=0.11). BMI (PB=0.43), TAS (PB=0.32)
and BDI (PB=0.30) were not significant predictors of the IGT
score at baseline nor were they significant predictors of the change
over time (BMI PB=0.16, TAS PB=0.41 and BDI PB=0.38). The two
groups differed in their change over time, with the full mental
capacity group doing better than the diminished mental capacity
group (PB=0.040; see Fig. 4). The PPP value for this model was 0.514.
Appreciation
The appreciation scores of the MacCAT-T were difficult to
analyse over time as the distribution was highly negatively skewed
(most participants scored 3 or higher). Therefore, we conducted a
mean comparison test in the Bayesian framework which allows
the normality assumption to be relaxed. The descriptive mean
scores, Bayesian P-values and standardised effect differences are
reported for each time point in Table 3. The group with full
mental capacity did well at baseline and kept appreciating well.
The group with diminished mental capacity differed noticeably at
baseline and after 2 years.
Discussion
This is the first large study into mental capacity to consent to treat‐
ment in people who are severely ill with AN using a longitudinal
design. The results of this follow-up study have two important
implications. First, prognosis seems more unfavourable for the
group with diminished mental capacity to consent to treatment.








After 1 year Diminished MC 69.8 16.3 14.0
Full MC 44.8 40.7 13.7
PB 0.03 0.05 0.49
BMI PB 0.42 0.16 0.16
After 2 years Diminished MC 53.9 10.8 35.8
Full MC 26.6 33.7 38.9
PB 0.03 0.05 0.48
BMI PB 0.45 0.32 0.27
MC, mental capacity; BMI, body mass index.
The P-value is the comparison between the diminished and full groups in each
column. For example, the first PB-value of 0.03 shows that the difference between























Fig. 3 Alexithymia scores between baseline, ﬁrst follow-up (after 1
year) and second follow-up (after 2 years) between the group with full
mental capacity (full) and the group with diminished mental capacity
(diminished), controlled for BMI (in kg/m2).
Elzakkers et al
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Participants with full mental capacity had a mild AN at follow-up,
whereas those with diminished mental capacity still fell within
the moderately ill category (DSM-541). And as the rise in BMI
mainly occurred in the first year after starting treatment
and the percentage of no and partial remission is significantly
higher in the group with diminished mental capacity, one would
not expect the diminished mental capacity group to reach full
remission in the near future. In the long run, diminished mental
capacity to consent to treatment means a higher likelihood of in-
patient treatment. These findings suggest a longer duration of care
for this particular group. Although the diminished mental capacity
group had a lower BMI at baseline, other parameters of prognostic
relevance such as duration of illness, percentage of participants
with the purging subtype of AN or comorbidity were equal
between the groups. Diminished mental capacity therefore seems
a factor of relevance to prognosis, next to the more obvious factor
of BMI. Both groups improved on BMI at 1 year follow-up and
maintained this improvement 1 year later at 2 year follow-up,
which is reassuring. Also, anxiety and depression levels lower
equally in the course of treatment, and remission rates after 2 years
were similar.
A second important finding in this study supports the
decision-making difficulties clinicians so clearly observe in every-
day practice on a more fundamental level. Using the IGT, it
has become clear that decision-making is more maladaptive in
people with diminished mental capacity, independent of BMI. The
IGT is based upon the theoretical model by Damasio (somatic
marker hypothesis42,43), which states that adaptive decision-
making is not a merely rational process but relies heavily on
emotional factors and ‘gut feeling’. Emotional dysregulation has
been found to be an important maintaining factor in AN.23,41,44–46
In this study, participants also displayed high levels of emotional
problems, such as severe depressive symptoms, a high level of
anxiety and moderate to high levels of alexithymia. Although
depression scores decreased significantly during treatment, levels
indicative of moderate depression still existed after 2 years. In
addition, in the diminished mental capacity group, alexithymia
levels remained at a clinical level even after weight improvement.
However, even after controlling for BMI, depression and alex-
ithymia, the diminished mental capacity group still performed
significantly worse on decision-making over time. This suggests
that the difference between groups cannot be fully explained by
the difference in emotional problems as measured in this study
(BDI, TAS). Appreciation of the diminished mental capacity
group over time remained less than that of the full mental
capacity group, linking the concept of more fundamental decision-
making (and ‘gut feeling’) to the concept of appreciation in AN.
Future research should therefore be focused on the interplay
between emotional dysregulation (as measured with more direct
markers) so often found in AN and the diminished appreciation
of illness and treatment.
The high level of emotional problems in our participants
support the emphasis laid on emotion recognition and processing
in recently developed cognitive–affective treatments for AN,
such as the Maudsley Anorexia Nervosa Treatment for Adults
(MANTRA47) and enhanced form of cognitive–behavioural therapy
(CBT-E48). In recent years, several randomised clinical trials have
been done that have shown that both MANTRA, CBT-E and
Focal Psychodynamic Therapy (FPT) have a positive effect on
outcome in AN.49–51 It is as yet not clear what works for whom.
Perhaps, MANTRA is of more value to people with AN with a
higher level of affective dysregulation, but this is speculative. Also
motivational stage of change might be an important factor,
although a recent study could only show a relation between the
stage of contemplation and the strength of the therapeutic alliance,
but not outcome.52,53
Strengths and limitations
Major strengths in this study are the longitudinal design, the high
participation after 1 and 2 year follow-up (80 and 70%, res‐
pectively) and the generalisability of the results, as this was a
naturalistic study. Also the assessment of decision-making on a
clinical as well as on a more fundamental level provided the
opportunity to bring together more basic science and bedside, a
strategy very fruitful to move forward in the body of knowledge
regarding an issue so complex as decision-making.
This study being a naturalistic study with hardly any exclusion
criteria, there were missing data in the course of follow-up. For a
clinical study with people with AN, who are usually highly avoi‐
dant of treatment,11,12 we consider the loss to follow-up of 20
and 29% after 1 and 2 years as acceptable. Also, in the statistical
analyses missing data were accounted for. Nevertheless, outcome
might have been influenced by these missing data.
Although clinicians doing the clinical judgment were masked
to the outcome of the MacCAT-T, for obvious reasons, they
could not be masked to their own assessment of mental capacity.
We do not think this resulted in treatment bias on the part of the
clinicians as this assessment is part of routine clinical practice,
especially in complex cases and therefore has not had a major
influence on treatment advised.
In our previously reported study,29 a substantial group was
found to have diminished capacity to consent to treatment.
Contrary to what might be expected, follow-up results show that
this particular group improves on both weight, eating disorder
Table 3 Appreciation scores over time between groups
Full mental capacity mean (s.d.) Diminished mental capacity mean (s.d.) Group difference PB Standardised effect
Baseline 3.8 (0.4) 3.5 (0.8) 0.02 0.25
One year follow-up 3.8 (0.5) 3.6 (0.5) 0.12 0.16



























Fig. 4 Iowa Gambling Task (IGT) scores between baseline, ﬁrst
follow-up (after 1 year) and second follow-up (after 2 years) between
the group with full mental capacity (full) and the group with
diminished mental capacity (diminished), controlled for BMI (in kg/m2),
depression and alexithymia scores.
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and more general psychopathology, which is encouraging. On
the down side, after 2 years BMI is still in the moderately severe
range and longer duration of care is expected. Decision-making on
a more fundamental level is maladaptive proposed to be caused
by an interaction between emotional dysregulation and lack of
appreciation of illness and treatment. Therefore, a key compo‐
nent in treatment should be to improve precisely this hampered
emotional functioning, a feature central to more recently devel-
oped AN treatments like MANTRA and CBT-E. Whether or not
the heightened focus on these emotional difficulties will improve
adaptive decision-making is an issue that should be assessed in
future research.
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